On January 3, 2024 Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, reported that Sanofi (NASDAQ: SNY) has exercised its option for a second target as part of the companies’ research collaboration to develop in vivo CRISPR-based therapeutics (Press release, Scribe Therapeutics, JAN 3, 2024, View Source [SID1234638940]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to advance our ongoing in vivo collaboration with Sanofi to address a second therapeutic target based on our progress to date working on potentially curative genetic medicines," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe. "Our teams have built a strong foundation combining Scribe’s engineered CRISPR technologies with Sanofi’s capabilities in genomic medicine. Together, we are dedicated to achieving our common goal of bringing breakthrough in vivo genetic medicines to patients in need."
CRISPR by Design, Scribe’s data-driven design and engineering approach for optimizing its CRISPR-based platforms and assets including X-Editing (XE) technologies, continues to drive forward a new era of truly transformative genetic medicines. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to advance in vivo medicines for genomic diseases.